174 related articles for article (PubMed ID: 28742794)
1. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Menon U; McGuire AJ; Raikou M; Ryan A; Davies SK; Burnell M; Gentry-Maharaj A; Kalsi JK; Singh N; Amso NN; Cruickshank D; Dobbs S; Godfrey K; Herod J; Leeson S; Mould T; Murdoch J; Oram D; Scott I; Seif MW; Williamson K; Woolas R; Fallowfield L; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Br J Cancer; 2017 Aug; 117(5):619-627. PubMed ID: 28742794
[TBL] [Abstract][Full Text] [Related]
2. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
[TBL] [Abstract][Full Text] [Related]
4. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Jacobs IJ; Menon U; Ryan A; Gentry-Maharaj A; Burnell M; Kalsi JK; Amso NN; Apostolidou S; Benjamin E; Cruickshank D; Crump DN; Davies SK; Dawnay A; Dobbs S; Fletcher G; Ford J; Godfrey K; Gunu R; Habib M; Hallett R; Herod J; Jenkins H; Karpinskyj C; Leeson S; Lewis SJ; Liston WR; Lopes A; Mould T; Murdoch J; Oram D; Rabideau DJ; Reynolds K; Scott I; Seif MW; Sharma A; Singh N; Taylor J; Warburton F; Widschwendter M; Williamson K; Woolas R; Fallowfield L; McGuire AJ; Campbell S; Parmar M; Skates SJ
Lancet; 2016 Mar; 387(10022):945-956. PubMed ID: 26707054
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Singh N; Ryan A; Karpinskyj C; Carlino G; Taylor J; Massingham SK; Raikou M; Kalsi JK; Woolas R; Manchanda R; Arora R; Casey L; Dawnay A; Dobbs S; Leeson S; Mould T; Seif MW; Sharma A; Williamson K; Liu Y; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Jacobs IJ; Parmar M
Lancet; 2021 Jun; 397(10290):2182-2193. PubMed ID: 33991479
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
Naumann RW; Brown J
Gynecol Oncol; 2018 Apr; 149(1):117-120. PubMed ID: 29398069
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
[No Abstract] [Full Text] [Related]
10. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I
J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255
[TBL] [Abstract][Full Text] [Related]
11. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
[TBL] [Abstract][Full Text] [Related]
12. The role of transvaginal ultrasound in screening for ovarian cancer.
Campbell S; Gentry-Maharaj A
Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
[TBL] [Abstract][Full Text] [Related]
13. The UKCTOCS experience--reasons for hope?
Menon U; Kalsi J; Jacobs I
Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S18-20. PubMed ID: 22543913
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.
Pavlik EJ
Womens Health (Lond); 2016 Sep; 12(5):475-479. PubMed ID: 27595999
[TBL] [Abstract][Full Text] [Related]
15. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ
Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551
[TBL] [Abstract][Full Text] [Related]
16. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
17. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
[No Abstract] [Full Text] [Related]
18. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
19. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henderson JT; Webber EM; Sawaya GF
JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
[TBL] [Abstract][Full Text] [Related]
20. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
Lu KH; Skates S; Hernandez MA; Bedi D; Bevers T; Leeds L; Moore R; Granai C; Harris S; Newland W; Adeyinka O; Geffen J; Deavers MT; Sun CC; Horick N; Fritsche H; Bast RC
Cancer; 2013 Oct; 119(19):3454-61. PubMed ID: 23983047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
